Unleashing the immune system to fight cancer | Oncolytics Biotech (original) (raw)

Currently, patients whose cancers are being treated with chemotherapy or immunotherapies such as immune checkpoint inhibitors (ICI) may only see limited benefits due to the ability of the tumor to adapt to and evade an immune attack. Pelareorep selectively replicates in cancer cells, generating innate and adaptive anticancer immune responses that can enhance oncology treatments. When added to existing treatment regimens for HR+/HER2- breast cancer and pancreatic cancer, pelareorep demonstrated the potential to extend survival times and reduce tumor burden.

The unique mechanism of action of pelareorep offers broad potential to help patients across a variety of indications. We have partnered with multiple academic and pharmaceutical collaborators to explore the expansive cancer-fighting potential of pelareorep.

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.